B4 androgen ablation: Attacking the prostate cancer stem cell

Journal of Clinical Investigation

Volumn 123, Issue 2, 2013, Pages 563-565

  Wicha, Max S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA6BETA4 INTEGRIN; ANDROGEN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KALININ; LAPATINIB; SCATTER FACTOR RECEPTOR; TRASTUZUMAB;

ANDROGEN ABLATIVE THERAPY; APOPTOSIS; CANCER STEM CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL RENEWAL; CELL SUBPOPULATION; CELL SURVIVAL; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR ABLATION;

ANIMALS; HUMANS; INTEGRIN BETA4; MALE; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS;

EID: 84873376298     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI67460     Document Type: Review

References (18)

1. Choi N, Zhang B, Zhang L, Ittmann M, Xin L. Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell. 2012;21(2):253-265.
2. Qin J, et al. The PSA (-/lo) prostate cancer cell population harbors self-renewing long-term tumorpropagating cells that resist castration. Cell Stem Cell. 2012;10(5):556-569.
3. Colombel M, et al. Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. Prostate. 2012;72(7):713-720.
4. Yoshioka T, et al. β4 Integrin signaling induces expansion of prostate tumor progenitors. J Clin Invest. 2013;123(2):682-699.
5. Lang SH, Anderson E, Fordham R, Collins AT. Modeling the prostate stem cell niche: an evaluation of stem cell survival and expansion in vitro. Stem Cells Dev. 2010;19(4):537-546.
6. Guo W, et al. Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell. 2006;126(3):489-502.
7. Korkaya H, et al. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009;7(6):e1000121.
8. Vermeulen L, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12(5):468-476.
9. Van Leenders GJ, et al. Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS One. 2011;6(11):e26753.
10. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. Science. 2010;329(5991):568-571.
11. Fillmore CM, et al. Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci U S A. 2010;107(50):21737-21742.
12. Joshi PA, et al. Progesterone induces adult mammary stem cell expansion. Nature. 2010;465(7299):803-807.
13. Fizazi K, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebocontrolled phase 3 study. Lancet Oncol. 2012;13(10):983-992.
14. Ziada A, et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate. 2004;60(4):332-337.
15. Ryan CJ, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013;19(1):215-224.
16. Smith DC, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial [published online ahead of print November 19, 2012]. J Clin Oncol. doi:10.1200/JCO.2012.45.0494.
17. Bretton PR, Melamed MR, Fair WR, Cote RJ. Detection of occult micrometastases in the bone marrow of patients with prostate carcinoma. Prostate. 1994;25(2):108-114.
18. Slamon DJ, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-792.